EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation

Jean Quancard iD, Anna Vulpetti iD, Anders Bach iD, Brian Cox iD, Stéphanie M Guéret, Ingo V Hartung iD, Hannes F Koolman, Stefan Laufer iD, Josef Messinger iD, Gianluca Sbardella iD, Russell Craft iD

ChemMedChem · 2023

DOI: 10.1002/cmdc.202300002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2023. Verfasst von Jean Quancard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Novartis Institute for Biomedical Research, Novartis Pharma AG, Novartis Campus, 4056, Basel, Switzerland. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Drug Discovery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hit generation is a crucial step in drug discovery that will determine the speed and chance of success of identifying drug candidates. Many strategies are now available to identify chemical starting points, or hits, and each biological target warrants a tailored approach. In this set of best practices, we detail the essential approaches for target centric hit generation and the opportunities and challenges they come with. We then provide guidance on how to validate hits to ensure medicinal chemistry is only performed on compounds and scaffolds that engage the target of interest and have the desired mode of action. Finally, we discuss the design of integrated hit generation strategies that combine several approaches to maximize the chance of identifying high quality starting points to ensure a successful drug discovery campaign.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemistry, PharmaceuticalDrug DiscoveryBiology

Stichwörter der Autor:innen

Best PracticesDELFBDDHTSHit GenerationScreening

Autor:innen und Institutionen

  • Global Discovery Chemistry, Novartis Institute for Biomedical Research, Novartis Pharma AG, Novartis Campus, 4056, Basel, Switzerland.
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.
  • School of Life Sciences, University of Sussex, Brighton, BN1 9RH, UK.
  • Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, 43183, Gothenburg, Sweden.
  • Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, 64293, Darmstadt, Germany.
  • Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany.

ORCID-Profile: Jean Quancard, Anna Vulpetti, Anders Bach, Brian Cox, Ingo V Hartung, Stefan Laufer, Josef Messinger, Gianluca Sbardella, Russell Craft

Zitieren

APA

Quancard, J., Vulpetti, A., Bach, A., Cox, B., Guéret, S. M., Hartung, I. V., Koolman, H. F., Laufer, S., Messinger, J., Sbardella, G., & Craft, R. (2023). The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation. ChemMedChem. https://doi.org/10.1002/cmdc.202300002

Vancouver

Quancard J, Vulpetti A, Bach A, Cox B, Guéret SM, Hartung IV, et al. The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation. ChemMedChem. 2023. doi:10.1002/cmdc.202300002

BibTeX
@article{Quancard2023,
  author = {Quancard, Jean and Vulpetti, Anna and Bach, Anders and Cox, Brian and Guéret, Stéphanie M and Hartung, Ingo V and Koolman, Hannes F and Laufer, Stefan and Messinger, Josef and Sbardella, Gianluca and Craft, Russell},
  title = {The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202300002}
}
Kostenlos starten →